Lyell Immunopharma Files 8-K on Material Agreement
Ticker: LYEL · Form: 8-K · Filed: Jul 25, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Jul 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, sec-filing
TL;DR
Lyell Immunopharma filed an 8-K on July 25th for July 24th events - material agreement, equity sales.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on July 25, 2025, reporting on events that occurred on July 24, 2025. The filing indicates the entry into a material definitive agreement, unregistered sales of equity securities, and includes Regulation FD disclosures and financial statements. Specific details regarding the agreement or sales are not provided in this excerpt.
Why It Matters
This 8-K filing signals significant corporate activity for Lyell Immunopharma, potentially involving new agreements or equity transactions that could impact its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and unregistered sales of equity, which can introduce financial and regulatory risks if not properly managed.
Key Numbers
- 001-40502 — SEC File Number (Identifies Lyell Immunopharma's filing with the SEC.)
- 83-1300510 — IRS Employer Identification No. (Tax identification number for Lyell Immunopharma.)
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- July 24, 2025 (date) — Date of earliest event reported
- July 25, 2025 (date) — Date of Report / Filing Date
- 201 Haskins Way South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Lyell Immunopharma?
The provided excerpt does not specify the details of the material definitive agreement.
What were the terms of the unregistered sales of equity securities?
The excerpt mentions unregistered sales of equity securities but does not provide specific terms or amounts.
What specific Regulation FD disclosures are being made in this filing?
The filing indicates Regulation FD Disclosure as an item, but the specific content of the disclosure is not detailed in this excerpt.
What are the key financial statements included with this 8-K?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in this excerpt.
What is Lyell Immunopharma's Standard Industrial Classification (SIC) code?
Lyell Immunopharma's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 25, 2025 regarding Lyell Immunopharma, Inc. (LYEL).